NASDAQ: PXDTPixie Dust Technologies Inc Stock
$2.51-0.08 (-3.09%)
Updated Apr 26, 2024
PXDT Price
$2.51
Fair Value Price
N/A
Market Cap
$36.90M
52 Week Low
$2.30
52 Week High
$10.51
P/E
-1.62x
P/B
2.44x
P/S
20.01x
PEG
N/A
Dividend Yield
N/A
Revenue
$5.75M
Earnings
-$14.89M
Gross Margin
71.7%
Operating Margin
-260.22%
Profit Margin
-263.9%
Debt to Equity
0.83
Operating Cash Flow
-$16M
Beta
0.84
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
PXDT Overview
Pixie Dust Technologies, Inc., a technology company, focuses on personal care and diversity, and workspace and digital transformation businesses primarily in Japan. It offers SonoRepro, an ultrasonic non-contact vibrotactile stimulation scalp care device; VUEVO, a series of directional voice arrival detection devices for individuals with deaf and hard-of-hearing; and kikippa, an acoustic stimulation device functioning as a desk-top speaker. The company also provides iwasemi, a sound-absorbing or sound-proofing material for architectural and interior design firms; hackke, a location positioning technology; KOTOWARI, a technology offering spatial analysis data; and magickiri, a planning services and monitoring service, which monitors human behavior and analyzes the customer's environment on the customer's behalf. In addition, it operates Pixie Nest, a membership forum, which hosts meetings and distributes information to facilitate solving social issues. The company was incorporated in 2017 and is headquartered in Tokyo, Japan.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how PXDT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
PXDT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
PXDT is good value based on its book value relative to its share price (2.44x), compared to the US Medical Devices industry average (3.7x)
P/B vs Industry Valuation
PXDT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more PXDT due diligence checks available for Premium users.
Be the first to know about important PXDT news, forecast changes, insider trades & much more!
PXDT News
Valuation
PXDT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.62x
Industry
28.63x
Market
41.14x
PXDT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.44x
Industry
3.7x
PXDT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
PXDT's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
PXDT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
PXDT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$27.3M
Liabilities
$12.4M
Debt to equity
0.83
PXDT's short-term assets ($20.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
PXDT's short-term assets ($20.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
PXDT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
PXDT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
PXDT vs Medical Device Stocks
Pixie Dust Technologies Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.